Radiopharm Theranostics Limited (RADX)

Market Cap	45.18M
Revenue (ttm)	8.79M
Net Income (ttm)	-24.06M
Shares Out	2.36B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,018
Open	5.43
Previous Close	5.62
Day's Range	5.43 - 6.84
52-Week Range	3.50 - 50.82
Beta	0.80
Analysts	Strong Buy
Price Target	15.00 (+133.41%)
Earnings Date	n/a

About RADX

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: NASDAQ
• Ticker Symbol: RADX

Financial Performance

In 2025, Radiopharm Theranostics's revenue was 13.40 million, an increase of 584.21% compared to the previous year's 1.96 million. Losses were -36.70 million, -23.45% less than in 2024.

Financial numbers in AUD

Analyst Summary

According to 3 analysts, the average rating for RADX stock is "Strong Buy." The 12-month stock price target is $15.0, which is an increase of 133.41% from the latest price.

Price Target

$15.0

(133.41% upside)

Analyst Consensus: Strong Buy